News
Breakthrough Study Shows Cognitive Training Improves Resilience for Warfighters
2+ mon, 1+ week ago (620+ words) SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Results from the Warfighter Brain Fitness Study, which recently published in the journal Military Medicine, show that the combination of two brain ... Breakthrough Study Shows Cognitive Training Improves Resilience for Warfighters SAN FRANCISCO, Jan. 12, 2026 (GLOBE…...
LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative...
5+ mon, 1+ week ago (807+ words) LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative... NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (LB Pharmaceuticals" or the Company") (Nasdaq:…...
Reunion Neuroscience Presents Full Data from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD) at ACNP Annual Meeting
1+ mon, 4+ week ago (426+ words) -- Met Primary Endpoint with 30mg Dose of RE104 with 23.0-Point Total Score Reduction in Montgomery-sberg Depression Rating Scale (MADRS) on Day 7 (p=0.0094) -- -- Demonstrated Rapid and Durable ... Reunion Neuroscience Presents Full Data from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum…...
Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
1+ mon, 2+ day ago (220+ words) This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. Although Helus Pharma is not advancing intravenous SPL026 in its…...
Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025
4+ mon, 1+ week ago (185+ words) Title: Brilaroxazine treatment effects on BDNF and inflammatory cytokines in schizophrenia: RECOVER trial in acute and stable patients over 1 year Session Name: A.10. Schizophrenia Session Number: ... Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label…...
HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health
4+ mon, 1+ week ago (864+ words) HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with…...
atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression
5+ mon, 2+ day ago (1140+ words) Breakthrough Therapy designation recognizes the potential of BPL-003 to deliver substantial improvement over existing therapies for patients with treatment-resistant depression FDA designation follows ... atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential…...
BD² and CareEvolution Partner to Provide New Digital Tool to Support Bipolar Disorder Study Participants
5+ mon, 3+ week ago (396+ words) Washington, D.C., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Breakthrough Discoveries for thriving with Bipolar Disorder (BD 2) and CareEvolution announced a new digital platform, BD 2 Connect, designed to ... BD" and CareEvolution Partner to Provide New Digital Tool to Support Bipolar Disorder Study Participants Washington, D.C., Sept....
Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
4+ mon, 3+ week ago (504+ words) The Phase 3 data will be presented by Ann Childress, M.D., a leading ADHD specialist and past President of the American Professional Society of ADHD and Related Disorders (APSARD). Her presentation, ... Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP…...
Spark Biomedical Awarded an NIH Grant to Study the Treatment Effects of tAN® for Alcohol Withdrawal Symptoms
4+ mon, 4+ week ago (542+ words) In this Phase I clinical study, Spark will collaborate with Menninger Clinic in Houston and Baylor College of Medicine, delivering tAN" therapy to patients enrolled in a five'day inpatient alcohol ... Spark Biomedical Awarded an NIH Grant to Study the Treatment…...